NCT00566917

Brief Summary

Pelvic organ prolapse is characterized by a lack of pelvic floor support causing the pelvic organs and vaginal walls to protrude. For decades, suture repair techniques have been the primary choice of surgical treatment when indicated. Traditional surgical techniques are frequently associated with unsatisfying anatomical recurrence rates and it is plausible that inherently weak, or damaged, pelvic floor supportive tissues need to be reinforced by a permanent support to avoid the high rates of recurrences commonly described using traditional techniques. Over the years sporadic attempts have been made to introduce novel surgical techniques using a variety of biomaterials with varying success. Despite a lack of clinical safety data, or compelling clinical evidence demonstrating that it improves outcomes compared to traditional suture techniques, use of biomaterials in pelvic reconstructive surgery has become widespread in just a few years . It is likely that biomaterials need to be "anchored" in tissues not afflicted by the disease, in order to provide the intended pelvic floor support. This has given rise to transvaginal surgical techniques using a transobturator approach passing the mesh through the arcus tendineous fascia pelvis, or the sacrospinous ligaments through a transgluteal approach. Short term data from concluded and on-going safety assessments of these techniques has provided promising results and satisfying clinical outcomes. The aim of the present study is to compare anterior mesh repair (PROLIFT®) with traditional suture repair in a randomised trial.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Dec 2007

Typical duration for phase_4

Geographic Reach
4 countries

53 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2007

Completed
1 day until next milestone

Study Start

First participant enrolled

December 1, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 4, 2007

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2010

Completed
Last Updated

January 29, 2010

Status Verified

May 1, 2008

Enrollment Period

2 years

First QC Date

November 30, 2007

Last Update Submit

January 28, 2010

Conditions

Keywords

VaginaProlapseAnterior vaginal wall prolapse

Outcome Measures

Primary Outcomes (1)

  • Combined primary outcome measure: anatomical assessment according to the pelvic organ prolapse quantification system and prolapse specific symptom

    One year

Secondary Outcomes (1)

  • Quality of life

    One year

Study Arms (2)

1

ACTIVE COMPARATOR

Anterior colporrhaphy (standardised)

Procedure: Anterior colporrhaphy

2

EXPERIMENTAL

Anterior PROLIFT

Procedure: Anterior PROLIFT

Interventions

Standardised colporrhaphy of the anterior vaginal wall

1

Transvaginal mesh surgery of the anterior vaginal wall

2

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Reproductive years in the past (biologically or reproductive decision)
  • Prolapse of the anterior vaginal wall ≥POPQ-stadium II
  • Prolapse specific pelvic symptom
  • Being able to make an informed consent on participation
  • Physically and cognitive capable of participating in the required follow-up
  • No other pelvic floor surgery performed at the time of anterior repair

You may not qualify if:

  • Previous or current pelvic organ cancer (regardless of treatment)
  • Severe rheumatic disease
  • Insulin treated diabetes mellitus
  • Connective tissue disorders (SLE, Sjögrens syndrome, Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis eller rheumatic myalgia)
  • Current systemic steroid treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (53)

Nyköbing Hospital

Nyköbing, Denmark

Location

Skejby Hospital

Skejby, Denmark

Location

Hyvinkää Hospital

Hyvinkää, Finland

Location

Jorvi Hospital

Jorvi, Finland

Location

Central Finland Central Finland

Jyväskylä, Finland

Location

Central Finland Central Hospital

Kotka, Finland

Location

South Carelian Central Hospital

Lappeenranta, Finland

Location

Lohja Hospital

Lohja, Finland

Location

Porvoo Hospital

Porvoo, Finland

Location

Lapland Central Hospital

Rovaniemi, Finland

Location

Åbo Hospital

Turku, Finland

Location

Akershus University Hospital

Ahus, Norway

Location

Haukeland Hospital

Bergen, Norway

Location

Innlandet Hospital

Brumunddal, Norway

Location

Bærum Hospital

Bærum, Norway

Location

Sörlandet Hospital

Flekkefjord, Norway

Location

Förde Hospital

Förde, Norway

Location

Ringerike Hospital

Hönefoss, Norway

Location

Kongsberg Hospital

Kongsberg, Norway

Location

Levanger Hospital

Levanger, Norway

Location

Namsos Hospital

Namsos, Norway

Location

Rikshospitalet

Oslo, Norway

Location

Telemark Hospital

Skien, Norway

Location

Stavanger University Hospital

Stavanger, Norway

Location

The Regional Hospital in Tromsø

Tromsø, Norway

Location

St Olav Hospital

Trondheim, Norway

Location

Borås Hospital

Borås, Sweden

Location

Höglandssjukhuset

Eksjö, Sweden

Location

Sahlgrenska Hospital

Gothenburg, Sweden

Location

Halmstad Hospital

Halmstad, Sweden

Location

Huddiksvall Hospital

Huddiksvall, Sweden

Location

Karlskoga Hospital

Karlskoga, Sweden

Location

Karlskrona Hospital

Karlskrona, Sweden

Location

Karlstad Hospital

Karlstad, Sweden

Location

Kristiansstad Hospital

Kristiansstad, Sweden

Location

Linköping University Hospital

Linköping, Sweden

Location

Sunderby Hospital

Luleå, Sweden

Location

Vrinnevi Hospital

Norrköping, Sweden

Location

Capio Läkargruppen Örebro

Örebro, Sweden

Location

Örebro University Hospital

Örebro, Sweden

Location

Skaraborg Hospital Skövde

Skövde, Sweden

Location

Södertälje Hospital

Södertälje, Sweden

Location

Danderyd University Hospital

Stockholm, Sweden

Location

Karolinska University Hospital Huddinge

Stockholm, Sweden

Location

S:t Göran Hospital

Stockholm, Sweden

Location

South Hospital

Stockholm, Sweden

Location

Sundsvall Hospital

Sundsvall, Sweden

Location

NÄL Hospital

Trollhättan, Sweden

Location

Uppsala Academic Hospital

Uppsala, Sweden

Location

Värnamo Hospital

Värnamo, Sweden

Location

Västerås Hospital

Västerås, Sweden

Location

Västervik Hospital

Västervik, Sweden

Location

Ystad Hospital

Ystad, Sweden

Location

Related Publications (3)

  • Yeung E, Baessler K, Christmann-Schmid C, Haya N, Chen Z, Wallace SA, Mowat A, Maher C. Transvaginal mesh or grafts or native tissue repair for vaginal prolapse. Cochrane Database Syst Rev. 2024 Mar 13;3(3):CD012079. doi: 10.1002/14651858.CD012079.pub2.

  • Elmer C, Falconer C, Hallin A, Larsson G, Ek M, Altman D; Nordic Transvaginal Mesh Group. Risk factors for mesh complications after trocar guided transvaginal mesh kit repair of anterior vaginal wall prolapse. Neurourol Urodyn. 2012 Sep;31(7):1165-9. doi: 10.1002/nau.22231. Epub 2012 Apr 19.

  • Altman D, Vayrynen T, Engh ME, Axelsen S, Falconer C; Nordic Transvaginal Mesh Group. Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. N Engl J Med. 2011 May 12;364(19):1826-36. doi: 10.1056/NEJMoa1009521.

MeSH Terms

Conditions

Uterine ProlapseProlapse

Condition Hierarchy (Ancestors)

Uterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesPelvic Organ ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Daniel Altman, MD, Assoc. prof.

    Karolinska Institutet

    STUDY CHAIR
  • Christian Falconer, MD, Assoc. prof.

    Karolinska Institutet at Danderyd University Hospital

    STUDY DIRECTOR
  • Daniel Altman, MD, Assoc. prof.

    Karolinska Institutet

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 30, 2007

First Posted

December 4, 2007

Study Start

December 1, 2007

Primary Completion

December 1, 2009

Study Completion

January 1, 2010

Last Updated

January 29, 2010

Record last verified: 2008-05

Locations